Tumor antigen vaccine

Global Cancer Peptide Therapeutics Drug Market Size Clinical Trials Insight 2026

Retrieved on: 
Wednesday, March 10, 2021
Clinical medicine, Medicine, Medical specialties, Cancer, Immunotherapy, Cancer vaccines, Vaccine, Tumor antigen vaccine

NEW DELHI, March 10, 2021 /PRNewswire/ -- "Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights:

Key Points: 
  • NEW DELHI, March 10, 2021 /PRNewswire/ -- "Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights:
    Global cancer Peptide Market Opportunity: > US$ 20 Billion By 2026
    Global Peptide Cancer Therapeutics Clinical Trials Overview by Company, Country, Indication, Phase & Formulation
    Cancer and its available treatments had been facing a huge debate regarding the efficacy as well as efficiency against specific cancer types but since the arrival of cancer immunotherapy and all the available therapies under it, the debates questioning the cancer market has come to an end.
  • Among all the therapies, the one that has been considered as a backbone for the overall progress of the cancer immunotherapy is cancer peptide vaccination.
  • Cancer peptide vaccination holds a strong potential towards treating solid tumors because the protocols that it is associated with it holds a strong clinical research platform.
  • The introduction of peptide vaccines into the cancer development has made a huge impact on the overall cancer therapeutics market.

ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, January 28, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Medical specialties, Clinical medicine, Medicine, Immune system, Oncology, Checkpoint inhibitor, Virotherapy, Cancer, T cell, Lung cancer, Cancer immunotherapy, Tumor antigen vaccine, ImmunityBio, NantKwest

These encouraging safety and efficacy data suggest that the addition of Anktiva to checkpoint inhibitors has the potential to restore and/or enhance sensitivity to checkpoint inhibitors.

Key Points: 
  • These encouraging safety and efficacy data suggest that the addition of Anktiva to checkpoint inhibitors has the potential to restore and/or enhance sensitivity to checkpoint inhibitors.
  • Tumor resistance to checkpoint therapy occurs when T cells are unable to recognize the tumor cell antigen.
  • Thus, the potential exists that Anktiva could be the combination backbone to all checkpoint therapy by activating both NK and T cells.
  • Lung cancer is the second most common cancer in men and women (excluding skin cancer), and non-small cell lung cancer accounts for 80% to 85% of all lung cancers, according to the American Cancer Society.

BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program

Retrieved on: 
Monday, January 25, 2021
Vaccination, Medical specialties, Medicine, Medical research, Health sciences, Vaccine, Virology, Cancer vaccine, Cancer, Tumor antigen vaccine

The case-to-fatality ratio is nearly three times that of breast cancer and makes ovarian cancer the deadliest gynecologic malignancy in developed countries.

Key Points: 
  • The case-to-fatality ratio is nearly three times that of breast cancer and makes ovarian cancer the deadliest gynecologic malignancy in developed countries.
  • In Phase I and Phase II clinical studies previously conducted by BioVaxys, co-founder and Chief Medical Officer, David Berd MD, using an earlier generation of the BioVaxys cancer vaccine on nearly 500 patients with melanoma or ovarian cancer, the haptenized cell platform showed significant clinical promise.
  • A way to achieve this is by the use of a hapten, which is the foundation for the BioVaxys' haptenized protein vaccine platform."
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program

Retrieved on: 
Monday, January 25, 2021
Vaccination, Medical specialties, Medicine, Medical research, Health sciences, Vaccine, Virology, Cancer vaccine, Cancer, Tumor antigen vaccine

The case-to-fatality ratio is nearly three times that of breast cancer and makes ovarian cancer the deadliest gynecologic malignancy in developed countries.

Key Points: 
  • The case-to-fatality ratio is nearly three times that of breast cancer and makes ovarian cancer the deadliest gynecologic malignancy in developed countries.
  • In Phase I and Phase II clinical studies previously conducted by BioVaxys, co-founder and Chief Medical Officer, David Berd MD, using an earlier generation of the BioVaxys cancer vaccine on nearly 500 patients with melanoma or ovarian cancer, the haptenized cell platform showed significant clinical promise.
  • A way to achieve this is by the use of a hapten, which is the foundation for the BioVaxys' haptenized protein vaccine platform."
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

NEUVOGEN Announces Participation at B. Riley Virtual Oncology Investor Conference

Retrieved on: 
Wednesday, January 20, 2021
Medical specialties, Clinical medicine, Medicine, Vaccination, Oncology, Cancer vaccine, Immunotherapy, Immune system, Tumor antigen, Vaccine, Tumor antigen vaccine, Active immunotherapy

SAN DIEGO, Jan. 20, 2021 /PRNewswire/ --NEUVOGEN todayannounced that Todd Binder, Chief Executive Officer of NEUVOGEN, will participate in the B. Riley Virtual Oncology Investor Conference:

Key Points: 
  • SAN DIEGO, Jan. 20, 2021 /PRNewswire/ --NEUVOGEN todayannounced that Todd Binder, Chief Executive Officer of NEUVOGEN, will participate in the B. Riley Virtual Oncology Investor Conference:
    NEUVOGEN, Inc. is an immunoncology company focused on whole cell cancer vaccine therapies.
  • NEUVOGEN's immunotherapies have the potential to deliver the broadest ever combination of tumor antigens to prime immune response.
  • Based in San Diego, California, NEUVOGEN's goal is to bring to market a pipeline of therapeutic cancer vaccines that activate the body's immune system to eradicate solid tumors and meaningfully extend the lives of patients while limiting side effects generally associated with traditional cancer treatments.
  • To learn more, visit www.neuvogen.com

Expanding Cancer Immunotherapy by Exploiting Recall Immunity -- A New Co-Therapy Option for Checkpoint Inhibitors, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, January 14, 2021
Clinical medicine, Medicine, Medical specialties, Virotherapy, Oncology, Cancer immunotherapy, Immunotherapy, Cancer, Checkpoint inhibitor, Cancer vaccine, Tumor antigen vaccine

Despite the significant improvement in prognosis for some cancer patients, there are challenges in using CIs for the treatment of all cancers.

Key Points: 
  • Despite the significant improvement in prognosis for some cancer patients, there are challenges in using CIs for the treatment of all cancers.
  • They are also not as effective in tumors with low mutational burden, due to the dependence on tumor "self" antigens for immune recognition.
  • Therefore, there is a need for a solution to improve the efficacy of CIs to make them applicable to the entire cancer patient population.
  • For more information, or to register for this event, visit Expanding Cancer Immunotherapy by Exploiting Recall Immunity A New Co-Therapy Option for Checkpoint Inhibitors.

Worldwide Dendritic Cell Cancer Vaccine Immunotherapy Industry to 2026 - Featuring 3M, Activartis and Argos Therapeutics Among Others

Retrieved on: 
Thursday, October 29, 2020
Medical specialties, Clinical medicine, Medicine, Vaccination, Vaccine, Immunotherapy, Cancer vaccine, Dendritic cell, Tumor antigen vaccine, Draft:Whole-cell cancer vaccine

The introduction of dendritic cell vaccine immunotherapy into the cancer therapeutics has caused several scientific and medical hurdles to overcome as the opportunities linked with dendritic cells treatment for the cancer patients are huge.

Key Points: 
  • The introduction of dendritic cell vaccine immunotherapy into the cancer therapeutics has caused several scientific and medical hurdles to overcome as the opportunities linked with dendritic cells treatment for the cancer patients are huge.
  • Dendritic cell vaccine immunotherapy among all the immunotherapy treatments is considered as the most potent antigen presenting cells for the proliferation of the T-cells.
  • The dendritic cell vaccine immunotherapy market is catalyzed by a completely and exciting novel range of disruptive technologies required for the re-definition of cancer therapeutics market.
  • Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
    Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
    Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
    Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
    Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
    Dosage, Efficacy & Price Insight of Provenge, Apceden & CreaVax

Global Dendritic Cell Cancer Vaccine Immunotherapy Market (2020 to 2026) - Dosage, Price & Clinical Trials Insight - ResearchAndMarkets.com

Retrieved on: 
Friday, October 23, 2020
Infectious diseases, Pharmaceutical, Health, Oncology, Clinical medicine, Medical specialties, Medicine, Vaccination, Immunotherapy, Dendritic cell, Cancer vaccine, Vaccine, Active immunotherapy, Tumor antigen vaccine

The "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The introduction of dendritic cell vaccine immunotherapy into the cancer therapeutics has caused several scientific and medical hurdles to overcome as the opportunities linked with dendritic cells treatment for the cancer patients are huge.
  • Dendritic cell vaccine immunotherapy among all the immunotherapy treatments is considered as the most potent antigen presenting cells for the proliferation of the T-cells.
  • The dendritic cell vaccine immunotherapy market is catalyzed by a completely and exciting novel range of disruptive technologies required for the re-definition of cancer therapeutics market.

Global Dendritic Cell Cancer Vaccine Therapy Immunotherapy Market Size Sales, Clinical Trials Report 2026

Retrieved on: 
Tuesday, October 20, 2020
Clinical medicine, Medicine, Medical specialties, Vaccination, Cancer vaccines, Cancer immunotherapy, Immunotherapy, Virotherapy, Vaccines, Cancer vaccine, Vaccine, Tumor antigen vaccine

"Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
    Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
    Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
    Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
    Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
    Hundreds of treatment regimens for the cancer patients are currently being performed and followed across the globe but none of the available cancer therapies have been able to provide a suitable and reliable treatment with 100% accuracy.
  • Few years back, the discovery of dendritic cell immunotherapy in the cancer therapeutic sector has led to a phase transition that is accompanied with latest technologies and unique set of mechanism against the cancer patients.
  • The unique approach followed by the therapy has made the researchers follow the therapy for the treatment of the cancer patients as well as conduct more clinical studies for extracting more applications from the therapy.
  • The accelerating discovery of therapy drugs in the clinical trials and the linked opportunities with the market is further delivering hidden insights about the progression and uniqueness of the therapy in cancer therapeutics market.

Global Dendritic Cell Cancer Vaccine Therapy Immunotherapy Market Size Sales, Clinical Trials Report 2026

Retrieved on: 
Tuesday, October 20, 2020
Clinical medicine, Medicine, Vaccination, Medical specialties, Immunotherapy, Cancer vaccine, Vaccine, Tumor antigen vaccine, Draft:Whole-cell cancer vaccine

USA, Europe, Japan & South Korea To Drive Global Dendritic Cell Cancer Vaccine Therapy Immunotherapy Market Technical Innovation With 3 New Vaccines Launch Over Next Decade, Says Kuick Research

Key Points: 
  • USA, Europe, Japan & South Korea To Drive Global Dendritic Cell Cancer Vaccine Therapy Immunotherapy Market Technical Innovation With 3 New Vaccines Launch Over Next Decade, Says Kuick Research
    "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
    Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
    Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
    Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
    Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
    Hundreds of treatment regimens for the cancer patients are currently being performed and followed across the globe but none of the available cancer therapies have been able to provide a suitable and reliable treatment with 100% accuracy.
  • Few years back, the discovery of dendritic cell immunotherapy in the cancer therapeutic sector has led to a phase transition that is accompanied with latest technologies and unique set of mechanism against the cancer patients.
  • The unique approach followed by the therapy has made the researchers follow the therapy for the treatment of the cancer patients as well as conduct more clinical studies for extracting more applications from the therapy.
  • The accelerating discovery of therapy drugs in the clinical trials and the linked opportunities with the market is further delivering hidden insights about the progression and uniqueness of the therapy in cancer therapeutics market.